Ads
related to: yescarta and tecartus rems- Prescribing Information
Find the Prescribing Information
and Important Safety Information.
- Treatment Information
CAR T Treatment
Information For HCPs
- Clinical Study Results
CAR T Treatment
Review Study Results
- Request A Rep
CAR T Treatment Option
Contact For More Info
- Prescribing Information
Search results
Results From The WOW.Com Content Network
The makers of the drugs — Bristol Myers Squibb, for Abecma and Breyanzi; Gilead Sciences' Kite Pharma, for Yescarta and Tecartus; Johnson & Johnson's Carvykti; and Novartis, for Kymriah ...
Brexucabtagene autoleucel, sold under the brand name Tecartus, is a cell-based gene therapy medication for the treatment of mantle cell lymphoma (MCL) [10] [11] [7] and acute lymphoblastic leukemia (ALL). [12] The most common side effects include serious infections, low blood cell counts and a weakened immune system. [10]
Currently approved products in that class include Abecma, Breyanzi, Carvykti, Kymriah, Tecartus and Yescarta, according to the announcement. Kymriah, ...
CAR-T therapies are approved under several products: Abecma, Breyanzi, Carvykti, Kymriah, Tecartus and Yescarta. FDA warns certain therapy to treat cancer may cause secondary cancer Skip to main ...
Axicabtagene ciloleucel, sold under the brand name Yescarta, is a medication used for the treatment for large B-cell lymphoma that has failed conventional treatment. [8] T cells are removed from a person with lymphoma and genetically engineered to produce a specific T-cell receptor .
Axicabtagene ciloleucel (KTE-C19, ZUMA-3, YESCARTA) was an investigational therapy (for the treatment of adult patients with relapsed or refractory acute lymphoblastic leukemia (ALL)) in which a patient's T cells were genetically modified to express a chimeric antigen receptor designed to target the antigen CD19, a protein expressed on the cell surface of B-cell lymphomas and leukemias. [11]
Ads
related to: yescarta and tecartus rems